Both pirfenidone and nintedanib reduced α-SMA expression, although only pirfenidone appeared to exert a statistically significant effect in these conditions at day three (control lung n = 2, IPF n = 3, fig. 2a) (p = 0.005). This evidence concerns the gene ACTA1 and idiopathic pulmonary fibrosis.